These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25303517)

  • 1. Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy.
    Smid A; Karas-Kuzelicki N; Milek M; Jazbec J; Mlinaric-Rascan I
    PLoS One; 2014; 9(10):e109551. PubMed ID: 25303517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
    Azimi F; Mortazavi Y; Alavi S; Khalili M; Ramazani A
    Leuk Res; 2015 Oct; 39(10):1048-54. PubMed ID: 26242828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inosine triphosphate pyrophosphohydrolase (ITPA) polymorphic sequence variants in Chinese ALL children and possible association with mercaptopurine related toxicity.
    Ma X; Zheng J; Jin M; Li W; Gao C; Zhang D; Chen Y; Li X; Xie J
    Int J Clin Exp Pathol; 2014; 7(7):4552-6. PubMed ID: 25120852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.
    Farfan MJ; Salas C; Canales C; Silva F; Villarroel M; Kopp K; Torres JP; Santolaya ME; Morales J
    BMC Cancer; 2014 Apr; 14():299. PubMed ID: 24774509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism.
    Kim H; Kang HJ; Kim HJ; Jang MK; Kim NH; Oh Y; Han BD; Choi JY; Kim CW; Lee JW; Park KD; Shin HY; Ahn HS
    PLoS One; 2012; 7(9):e45558. PubMed ID: 23029095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
    Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
    Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
    J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
    Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
    Stocco G; Cheok MH; Crews KR; Dervieux T; French D; Pei D; Yang W; Cheng C; Pui CH; Relling MV; Evans WE
    Clin Pharmacol Ther; 2009 Feb; 85(2):164-72. PubMed ID: 18685564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
    Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.
    Smid A; Karas-Kuzelicki N; Jazbec J; Mlinaric-Rascan I
    Sci Rep; 2016 Jul; 6():30244. PubMed ID: 27452984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.
    Dorababu P; Nagesh N; Linga VG; Gundeti S; Kutala VK; Reddanna P; Digumarti R
    Eur J Clin Pharmacol; 2012 Apr; 68(4):379-87. PubMed ID: 22009189
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Rosdiana DS; Saputri DS; Louisa M; Setiabudy R
    In Vivo; 2024; 38(4):2041-2048. PubMed ID: 38936894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
    Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
    Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6.
    Atanasova S; Shipkova M; Svinarov D; Mladenova A; Genova M; Wieland E; Oellerich M; von Ahsen N
    Ther Drug Monit; 2007 Feb; 29(1):6-10. PubMed ID: 17304144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.
    Suzuki H; Fukushima H; Suzuki R; Hosaka S; Yamaki Y; Kobayashi C; Sakai A; Imagawa K; Iwabuchi A; Yoshimi A; Nakao T; Kato K; Tsuchida M; Kiyokawa N; Koike K; Noguchi E; Fukushima T; Sumazaki R
    J Hum Genet; 2016 Sep; 61(9):797-801. PubMed ID: 27193222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
    Adam de Beaumais T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2011 Apr; 71(4):575-84. PubMed ID: 21395650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children.
    Tanaka Y; Manabe A; Nakadate H; Kondoh K; Nakamura K; Koh K; Utano T; Kikuchi A; Komiyama T
    Leuk Res; 2012 May; 36(5):560-4. PubMed ID: 22200619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.